CDK4 and neoplasm: Less is known about the effects of CDK4/6 inhibition on melanoma cells, however, an increase in MHC I in the mouse melanoma cell line B16-OVA in response to CDK4/6 inhibition has been reported, which led to enhanced T cell recognition in vitro (108), In breast cancer preclinical models and patients, induction of tumor-intrinsic interferon signaling is observed in response to CDK4/6i, which may enhance tumor immunogenicity by promoting increased secretion of T cell chemoattractants and expression of costimulatory genes (108) (Figure 3).